%A Geier,Brian %A Kurmashev,Dias %A Kurmasheva,Raushan T. %A Houghton,Peter J. %D 2015 %J Frontiers in Oncology %C %F %G English %K Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s,xenografts,childhood cancer,Preclinical Pharmacology,bioinformatics,Data Mining %Q %R 10.3389/fonc.2015.00193 %W %L %M %P %7 %8 2015-August-26 %9 Review %+ Peter J. Houghton,Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio,USA,houghtonp@uthscsa.edu %# %! Mining preclinical drug sensitivity data %* %< %T Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation %U https://www.frontiersin.org/articles/10.3389/fonc.2015.00193 %V 5 %0 JOURNAL ARTICLE %@ 2234-943X %X Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and “omics” approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.